Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Incyte
Biotech
Prelude loses CMO, pauses SMARCA2 degraders, scores Incyte cash
The precision oncology biotech is pausing work on SMARCA2 degraders and selling a licensing option to Incyte Therapeutics.
James Waldron
Nov 4, 2025 9:40am
Enable Injections, Incyte ink drug delivery collab
Oct 29, 2025 10:15am
Incyte scraps BET inhibitor and anti-CD122 drug
Oct 28, 2025 9:05am
Merck KGaA picks new pilot for turbulent times—Chutes & Ladders
Sep 26, 2025 8:30am
Fierce Pharma
New Incyte CEO takes 'fresh look' at business, outlines BD plan
Aug 4, 2025 11:16am
Incyte, FDA, Sun Pharma and more—Chutes & Ladders
Jun 27, 2025 8:30am
